ALTSTATION.IO

Gilead Sciences, Inc. (GILD) Stock Analysis

By Nova Skye | AltStation.io | Updated September 19, 2026

Price

$144.91

Change

-0.51%

Market Cap

$179.68B

Avg Volume

6.9M

Company Overview

Gilead Sciences is a major biopharmaceutical company based in Foster City, California, operating in the general drug manufacturing space since 1987. The company discovers, develops, and sells prescription medicines across the United States, Europe, and international markets. Its commercial foundation is built on antiviral therapies for HIV-1, headlined by treatments like Biktarvy, Descovy, Genvoya, and Sunlenca. Beyond HIV, Gilead sells liver disease treatments including Epclusa, Livdelzi, and Vemlidy, alongside Veklury for COVID-19 and AmBisome for serious fungal infections.

Gilead is an entrenched market leader in antiviral treatments, but it operates as a challenger in oncology and cell therapy. Its primary edge is a dominant, cash-generative HIV franchise, though sustaining that position requires continuous lifecycle management. To diversify away from virology concentration risk, Gilead has built an oncology footprint with its CAR T-cell therapies Yescarta and Tecartus, as well as Trodelvy. It aggressively reinforces its competitive position through external dealmaking with partners like Merck, Arcus Biosciences, and Merus.

Right now, Gilead is executing a strategic pivot to establish itself as a diversified oncology and immunology player. While mature antiviral drugs still fund daily operations, the company is directing substantial focus toward cancer immunotherapies and specialized drug development. Key collaborative efforts underscore this push, including trispecific antibody research with Merus and small molecule programs with LEO Pharma and Terray Therapeutics. Gilead needs these pipeline alliances to deliver commercial hits to secure its next leg of revenue growth.

Key Financials

Market Cap

$179.68B

Revenue

$30.46B

EBITDA

$14.60B

Gross Margin

79.6%

Profit Margin

-10.6%

Revenue Growth

10.2%

Total Cash

$4.88B

Total Debt

$26.25B

Free Cash Flow

$9.77B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

N/A

Forward P/E

14.65

Beta

0.35

52-Week High

$157.29

52-Week Low

$108.46

EPS

$-2.65

50-Day Avg

$137.37

200-Day Avg

$134.55

Price/Book

15.20

Technical Analysis

GILD trades at $144.91, 78% of the way from its 52-week low of $106.44 to its high of $155.38. The stock is 6.80% below that high and 36.05% above the low. Price sits 0.79% below the 20-day moving average of $145.97. Five-day momentum is negative at 3.21%, while 20-day momentum remains positive at 6.58%. Near-term support is $130.21, and resistance is $151.22.

Recent News and Developments

Gilead opens 182,000-square-foot research center

Gilead opened a five-story research center in Foster City focused on oncology, inflammation and research data science. The facility supports about 325 employees, including 260 laboratory scientists, and is part of Gilead’s planned $32 billion U.S. investment through 2030. Source: Nasdaq

Assembly Bio commits to Gilead’s HSV program

Assembly Biosciences exercised its option to fund 40% of U.S. development costs and receive 40% of U.S. profits from Gilead’s herpes simplex virus program. GS-1179 is expected to enter a Phase 2 trial for recurrent genital herpes by the end of 2026, while Gilead retains control of development and commercialization. Source: Assembly Biosciences

GILD drops 2.88% in one session

Gilead shares closed at $146.64 on September 8, down 2.88% for the session versus a 0.58% decline in the S&P 500. The stock had still gained 13.48% over the preceding month, beating the medical sector’s 2.73% gain. Source: Zacks

Market Sentiment and Analyst Recommendations

Bull Case

Revenue is $30.46 billion and growing 10.2%, giving Gilead a solid operating base. The analyst consensus is buy across 27 analysts, with a $157.41 target and a high estimate of $180.00. Gilead is investing in growth, including a new 182,000-square-foot research center supporting about 325 employees. That facility advances oncology, inflammation, and research data science as part of a planned $32 billion U.S. investment through 2030. Assembly Biosciences also committed to fund 40% of U.S. development costs for Gilead’s herpes simplex virus program in exchange for 40% of U.S. profits. With GS-1179 expected to enter a Phase 2 trial by the end of 2026, the pipeline has a clear near-term catalyst, and the stock remains below both its $151.22 near-term resistance and $157.41 analyst target.

Bear Case

GILD has $26.25 billion in total debt against $4.88 billion in cash, creating a meaningful balance-sheet gap. The P/E ratio is unavailable, so investors cannot assess the stock using the provided earnings multiple. Price is already 78% through its 52-week range and only 6.80% below the $155.38 high, leaving less technical room before prior highs become a hurdle. Short-term momentum has weakened, with the stock down 3.21% over five trading days and 0.79% below its 20-day moving average. The September 8 session also showed sharp downside sensitivity: GILD fell 2.88% while the S&P 500 declined 0.58%. Pipeline diversification requires execution, and GS-1179 is not expected to enter Phase 2 until the end of 2026.

What to Watch

The first technical test is whether GILD can reclaim its 20-day moving average at $145.97. A move through $151.22 would clear the stated 30-day resistance and put the $155.38 52-week high back in focus. A decline toward $130.21 would test near-term support and weaken the current 20-day momentum reading of 6.58%. Investors should track progress toward the planned Phase 2 trial for GS-1179 by the end of 2026. Pipeline updates in oncology and inflammation will show whether Gilead’s diversification beyond virology is producing tangible progress. Revenue growth is the key operating metric: the current benchmark is 10.2%, and any change would directly affect the growth thesis.

Analyst Consensus

BUY

Based on 27 analyst opinions

Low Target

$123.00

Mean Target

$157.41

High Target

$180.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

17,000

Earnings & Dividends

Next Earnings

Oct 29, 2026

EPS (Trailing)

$-2.65

Dividend Yield

225.0%

Payout Ratio

43.4%

Frequently Asked Questions

Is GILD a good stock to buy?

The recommendation is buy based on 27 analysts, and revenue growth is 10.2%. The takeaway is that analyst sentiment and growth support the bull case, although the stock already sits 78% through its 52-week range.

What is GILD’s analyst price target?

The analyst target is $157.41, with estimates ranging from $123.00 to $180.00. The takeaway is that expectations vary widely around the current $144.91 price.

What are GILD’s support and resistance levels?

Near-term support is $130.21, based on the 30-day low, while resistance is $151.22, based on the 30-day high. The takeaway is that these are the key levels to monitor around the current price.

How strong is GILD’s recent momentum?

GILD is down 3.21% over the last five trading days but up 6.58% over the last 20 trading days. The takeaway is that the broader short-term trend is positive, but immediate momentum has weakened.

Does GILD pay a dividend?

Dividend data was not provided, so no factual conclusion can be made from the available figures. The takeaway is that investors should verify the current dividend separately before using income as part of the thesis.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated September 19, 2026.